59 G. B. Marks et al., “The Effect of Neonatal BCG Vaccination on Atopy and Asthma at Age 7 to 14 Years: An Historical Cohort Study in a Community with a Very Low Prevalence of Tuberculosis Infection and a High Prevalence of Atopic Disease”, Journal of Allergy and Clinical Immunology 111 (2003), 541–549; C. B. Saanjeevi et al., “BCG Vaccination and GAD65 and IA-2 Autoantibodies in Auto-immune Diabetes in Southern India”, Annals of the New York Academy of Sciences 958 (2002), 293–296; Ramesh Bhonde and Pradeep Prab, “Can We Say Bye to BCG?” Current Science 77 (1999), 1283.

60 A. B. Alexandroff et al., “BCG Immunotherapy of Bladder Cancer: 20 Years On”, Lancet 9165 (1999), 1689–1694.

61 Судя по обзору медицинской литературы по состоянию на 1999 г., использование вакцины Коули обеспечивало уровень коэффициента выживаемости, сравнимый с тем, которого добивались онкологи, лечившие те же разновидности опухолей современными методами. Stephen Hoption Cann et al., “Dr. William Coley and Tumour Regression, a Place in History or in the Future”, Postgraduate Medicine 79 (2003), 672–680.

62 Mary Ann Richardson et al, “Coley Toxins Immunotherapy, a Retrospective Review”, Alternative Therapies in Health and Medicine 5 (1999), 42–47.

63 Аллергия и астма: L. Camporota et al., “Effects of Intradermal Injection of SRL 172 on Allergen-Induced Airway Responses and IL-5 Generation by PBMC in Asthma”, Respiratory and Critical Care Medicine 161 (2000); Peter Arkwright et al., “Intradermal Administration of a Killed Mycobacterium vaccae Suspension (SRL 172) Is Associated with Improvement in Atopic Dermatitis in Children with Moderate-to-Severe Disease”, Journal of Allergy and Clinical Immunology 107 (2001), 531–534; L. Camporota et al., “The Effects of Mycobacterium vaccae on Allergen-Induced Airway Responses in Atopic Asthma”, European Respiratory Journal 21 (2003), 287293. Рак: L. Assersohn et al, “A Randomised Pilot Study of SRL 172 (Mycobacterium vaccae) in Patients with Small Cell Lung Cancer Treated with Chemotherapy”, Clinical Oncology 14 (2002), 23–27; R. Mendes et al., “Clinical and Immunological Assessment of Mycobacterium vaccae (SRL 172) with Chemotherapy in Patients with Malignant Mesethelioma”, British Journal of Cancer 86 (2002), 336–341; S. Nicholson et al., “A Randomized Phase II Trials of SRL 172 (Mycobacterium vaccae) +/– Low-Dose Interleukin-2 in the Treatment of Metastatic Malignant Melanoma”, Melanoma Research 13 (2003), 389–393; A. Maraveyas et al., “Possible Improved Survival of Patients with Stage IV AJCC Melanoma Receiving SRL 172 Immunotherapy: Correlation with Induction of Increased Levels of Intracellular Interleukin-2 in Peripheral Blood Lymphocytes”, Annals of Oncology 10 (1999), 817–824; P. M. Patel et al., “An Evaluation of a Preparation of Mycobacterium vaccae (SRL172) as an Immunotherapeutic Agent in Renal Cancer”, European Journal of Cancer 44 (2008), 216–223.